Latest Conference Articles

Christian Ruff, MD, MPH shared the results of the AZALEA-TIMI 71 trial.

Leonard Egede, MD, MS, FACP discussed the association of historical redlining and contemporary structural racism on life expectancy.

Twice-yearly dosing could significantly improve adherence rates.

Rebekah Walker, PhD raises awareness of the long-lasting health implications caused by historic redlining.

Value-based payment models are becoming increasingly common, leading clinicians to find novel ways to engage patients and improve disease control with the goal of reducing morbidity, mortality, and cost.

Within the Veterans Health Administration System, primary care pharmacists are embedded in primary care panels and work alongside primary care physicians and nurses to optimize medication management for patients.

Improving collaboration and communication between all members of the health care team is one way to address these challenges.

Milind Desai, MD, MBA shares insight into the REMS program for patients with obstructive hypertrophic cardiomyopathy.

This is the first trial that tested the effect of any medication on major heart failure outcomes in patients with HFpEF and obesity, according to investigators.

The system, currently in early development in Japan, could minimize the need for blood tests, blood pressure cuffs, or expensive wearable devices.

The global temperature has risen by an average of 0.11° Fahrenheit per decade since 1850, or about 2 degrees in total.

Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, CACP will be moderating a session about social determinants of health and heart failure.

Community pharmacists are playing an increasing role in sexual and reproductive health services and can provide that trustworthy information to patients.

Blaine Groat, PharmD, discusses the evolution of US Pharmacopeia (USP)'s drug standards, highlighting new compounding guidelines, as well as USP’s commitment to pharmacogenomics and upcoming opportunities for experts to contribute to personalized medicine standards.

The sessions will include late-breaking science, clinical practice guidelines, early innovators spotlight sessions, and more.

The 2024 American Association of Colleges of Pharmacy Annual Meeting took place from July 20 to July 23, 2024, in Boston, Massachusetts.

Two clinical trials with MRD monitoring may be practice changing: TRACERx and AEGEAN.

ASCO is prioritizing the expansion of pharmacist involvement in its organization by recognizing pharmacists' contributions to safety standards, quality improvement initiatives, and certification programs.

Gut microbiome research is no longer an obscure field in cancer care.

Targeted therapies, CDK4/6 inhibitors, and precision medicine are improving outcomes for patients with high-risk and metastatic disease.

Rising cancer rates and costs pose challenges in global oncology markets amid AI and targeted therapy breakthroughs.

Experts from Moffitt Cancer Center discuss the benefit of multidisciplinary teams in lung cancer care.

The 2024 NCODA International Fall Summit took place in Orlando, Florida, from October 23 to October 25.

This model, which uses technology that discovers black holes, pulls from real data to evaluate cancer treatments, optimizing treatment choices for patients with different cancers.

Liz Vogel, CPhT-Adv, CSPT, discusses the procedures and best practices for safe compounding of hazardous and non-hazardous drugs.

The investigators note that these findings are significant because bile duct cancer is a rare disease with limited treatments and low survival rates.

Glucagon-like peptide-1 (GLP-1) receptor agonists are widely known as treatments for type 2 diabetes, though some have been approved for indications beyond diabetes.

Results demonstrating safety and efficacy in those with anemia in non-dialysis dependent chronic kidney disease and anemia in dialysis-dependent chronic kidney disease were presented at the 2024 American Society of Nephrology Kidney Week.